Acadian Asset Management LLC Takes Position in Ocuphire Pharma, Inc. (NASDAQ:OCUP)

Acadian Asset Management LLC bought a new stake in shares of Ocuphire Pharma, Inc. (NASDAQ:OCUP) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 28,245 shares of the company’s stock, valued at approximately $122,000.

A number of other hedge funds have also recently modified their holdings of OCUP. Rice Hall James & Associates LLC boosted its stake in Ocuphire Pharma by 0.4% in the 1st quarter. Rice Hall James & Associates LLC now owns 809,117 shares of the company’s stock worth $3,034,000 after purchasing an additional 3,050 shares in the last quarter. Trust Co. of Toledo NA OH boosted its stake in Ocuphire Pharma by 24.6% in the 2nd quarter. Trust Co. of Toledo NA OH now owns 32,399 shares of the company’s stock worth $141,000 after purchasing an additional 6,399 shares in the last quarter. Geode Capital Management LLC boosted its stake in Ocuphire Pharma by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 181,370 shares of the company’s stock worth $680,000 after purchasing an additional 8,303 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Ocuphire Pharma by 4.4% in the 3rd quarter. Renaissance Technologies LLC now owns 206,901 shares of the company’s stock worth $416,000 after purchasing an additional 8,711 shares in the last quarter. Finally, Kestra Private Wealth Services LLC bought a new position in Ocuphire Pharma in the 1st quarter worth about $32,000. Institutional investors own 17.37% of the company’s stock.

Ocuphire Pharma Stock Performance

Shares of NASDAQ:OCUP opened at $2.90 on Tuesday. Ocuphire Pharma, Inc. has a fifty-two week low of $2.48 and a fifty-two week high of $6.60. The business has a 50-day simple moving average of $3.30 and a two-hundred day simple moving average of $3.87. The firm has a market cap of $65.65 million, a price-to-earnings ratio of 2.21 and a beta of 0.24.

Analyst Ratings Changes

OCUP has been the subject of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $17.00 target price on shares of Ocuphire Pharma in a research report on Monday, August 14th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Ocuphire Pharma in a research report on Tuesday, November 14th.

Ocuphire Pharma Company Profile

Ocuphire Pharma, Inc, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia.